Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist

Compiled from ClinicalTrials.gov and CTIS registry records · Last verified 26 Sep 2026 · Editorial standards

At a glance

Tongji Hospital is the lead sponsor of 142 current clinical trials in our China register. 91 are recruiting patients now. The most common phase is Not applicable. The drugs named most often in its trials are Cisplatin, Lenvatinib and Sintilimab. The most-studied condition is Ovarian Cancer.

ClinicalTrials.gov trials by status

Recruiting9164%
Not yet open3525%
Active, closed96%
By invitation75%

Trials by phase

Not applicable4431%
Observational4230%
Phase 21813%
Phase EARLY_PHASE196%
Phase 486%
Phase 375%
Phase 175%
Phase 1/254%
Phase 2/321%

Clinical trials sponsored by Tongji Hospital

142 on ClinicalTrials.gov

Study	Phase	Status	Start	Registers
Fluzoparib+Bevacizumab/Dietary Intervention vs Fluzoparib Monotherapy as First-line Maintenance in HRD+/- Advanced Ovarian Cancer NCT06954584 · Ovarian Cancer Drugs: Bevacizumab, Fluzoparib	Phase 3	Recruiting	2025-05	China
Circulating Tumor Mitochondrial DNA (ct-mtDNA) As a Biomarker for Hepatocellular Carcinoma Recurrence Surveillance NCT06653062 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma (HCC)	Observational	Recruiting	2024-11	China
Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Mediated Neurological Autoimmune Diseases. NCT07526493 · ClinicalTrials.gov ↗ · Multiple Sclerosis (MS), Neuromyelitis Optica Spectrum Disorder (NMOSD), Autoimmune Encephalitis (AE) Drugs: Cyclophosphamide, Fludarabine	Phase 1	Recruiting	2026-04	China
A Prospective Observational Study of First-Line Systemic Therapy Combined With Celiac Plexus Blockade for Advanced Biliopancreatic Cancer With Pain NCT07326137 · ClinicalTrials.gov ↗ · Advanced Biliary Tract Cancer(BTC), Advanced Pancreatic Cancers, Cancer-related Pain	Observational	Recruiting	2025-12	China
Neoadjuvant Chemoimmunotherapy and Extrafascial Hysterectomy for IB2 Cervical Cancer NCT06289751 · ClinicalTrials.gov ↗ · Cervical Cancer, Neoadjuvant Chemoimmunotherapy, Radical Hysterectomy Drugs: Cadonilimab, Cisplatin, Paclitaxel-albumin	Phase 2	Recruiting	2024-09	China
A Real-world Study of Staging and Grading of Clinical Immune Status in Chronic Hepatitis B NCT06525909 · ClinicalTrials.gov ↗ · Hepatitis B, Chronic	Observational	Recruiting	2024-01	China
Spinal Versus General Anesthesia on Postoperative Pulmonary Complications NCT06425627 · ClinicalTrials.gov ↗ · Pulmonary Complication, Anesthesia, Hip Fractures	Not applicable	Recruiting	2024-06	China
The Safety, Tolerability, and Efficacy of KD01 in Gynecologic Malignancies NCT06552598 · ClinicalTrials.gov ↗ · Cervical Cancer, Gynecologic Malignancies, Endometrial Cancer Drug: KD01	Phase 1	Recruiting	2024-04	China
INVIGORATE: A Study of QL1706 and Bevacizumab in Advanced First-Line Ovarian Clear Cell Carcinoma NCT07002346 · ClinicalTrials.gov ↗ · Ovarian Clear Cell Carcinoma Drugs: Bevacizumab, Carboplatin, Iparomlimab and Tuvonralimab	Phase 3	Recruiting	2025-11	China
Iparomlimab and Tuvonralimab as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma With High Risk of Recurrence NCT06954116 · ClinicalTrials.gov ↗ · Resectable Hepatocellular Carcinoma With High Risk of Recurrence Drug: Iparomlimab and Tuvonralimab	Phase 2	Recruiting	2025-08	China
Neoadjuvant Chemotherapy Plus Camrelizumab for FIGO Stage IB1 Cervical Cancer NCT06289062 · ClinicalTrials.gov ↗ · Cervical Cancer, Neoadjuvant Chemoimmunotherapy, Fertility Preservation Drugs: Camrelizumab, Cisplatin, Nab-paclitaxel	Phase 2	Recruiting	2024-05	China
Wearable Device-Based Early Warning of Postoperative Complications in Thoracic Surgery NCT07646730 · ClinicalTrials.gov ↗ · Postoperative Complications, Thoracic Surgery, Perioperative Monitoring	Observational	Recruiting	2025-12	China
To Explore the Value of New MR Technology in Non-invasive Quantitative Assessment of Systemic Metabolism, Disease Status and Prognosis in Patients With Metabolic-Associated Fatty Liver Disease NCT07149571 · ClinicalTrials.gov ↗ · Nonalcoholic Fatty Liver Disease, Metabolic-associated Fatty Liver Disease	Observational	Recruiting	2025-04	China
Efficacy and Safety of Sanggua Tablets in the Treatment of Patients With Impaired Glucose Tolerance and Mild Type 2 Diabetes NCT06964620 · ClinicalTrials.gov ↗ · Diabetes Mellitus, Type 2, Impaired Glucose Tolerance	Phase EARLY_PHASE1	Recruiting	2025-05	China
The Safety and Efficacy of NouvSoma001 in Neuromyelitis Optica Spectrum Disorders NCT06620809 · ClinicalTrials.gov ↗ · Neuromyelitis Optica Spectrum Disorders	Phase 1	Recruiting	2025-03	China
The Effects of Hydroxychloroquine in Patients with Inflammatory Cardiomyopathy NCT05961202 · ClinicalTrials.gov ↗ · Inflammatory Cardiomyopathy, Myocarditis Drugs: Hydroxychloroquine, Prednisolone	Phase 2/3	Recruiting	2021-11	China
Efficacy and Safety of Calculus Bovis Sativus (CBS) for Adult Encephalitis (CBSinEncephalitis) NCT06584045 · ClinicalTrials.gov ↗ · Encephalitis, Encephalitis, Viral, Autoimmune Encephalitis Caused by N-Methyl D-Aspartate Receptor Antibody Drug: Calculus bovis sativus	Not applicable	Recruiting	2024-09	China
Effect of Full-House ESS With Nasopharyngeal Lymphoid Tissue Ablation on Nasal Polyps NCT07245329 · ClinicalTrials.gov ↗ · Nasal Polyps	Not applicable	Recruiting	2025-07	China
Construction of AI Model for Precision Imaging Diagnosis of Cranial Diseases NCT07446842 · ClinicalTrials.gov ↗ · Cranial Diseases (e.g., Brain Tumors, Stroke, Neurodegenerative Disorders)	Observational	Recruiting	2026-01	China
Intelligent Segmentation Algorithm of Ultrasonic Image NCT06646679 · ClinicalTrials.gov ↗ · Segmentation	Observational	Recruiting	2024-10	China
Neoadjuvant Cardonilizumab Combined With Neoadjuvant Chemoradiotherapy Can Resect Locally Advanced Esophageal Squamous Cell Carcinoma NCT07699185 · ClinicalTrials.gov ↗ · Esophageal Squamous Cell Carcinoma Drugs: Cardonilizumab, Cisplatin, Paclitaxel	Phase 2	Recruiting	2024-01	China
Safety and Efficacy of PRG-2311 for Refractory Lupus Nephritis and IgG4-Related Disease NCT06497361 · ClinicalTrials.gov ↗ · Lupus Nephritis, IgG4-related Disease	Phase EARLY_PHASE1	Recruiting	2024-07	China
An In-situ Detection for MicroRNA NCT06529614 · ClinicalTrials.gov ↗ · Breast Cancer	Observational	Recruiting	2024-07	China
Oliceridine-Enhanced Analgesia and Recovery: A G-Protein Biased μ-Opioid Study NCT06409689 · ClinicalTrials.gov ↗ · Postoperative Analgesia Drugs: Morphine, Oliceridine fumarate	Not applicable	Recruiting	2024-06	China
A Clinical Study of Glycerol Phenylbutyrate in Chinese Patients With Urea Cycle Disorders NCT06904027 · ClinicalTrials.gov ↗ · Urea Cycle Disorders	Observational	Recruiting	2025-12	China
Intraoperative Paravertebral Block and Postoperative Complications NCT07211529 · ClinicalTrials.gov ↗ · Video-assisted Thoracoscopic Surgery (VATS), Lung Cancer (Diagnosis), Pulmonary Infections	Not applicable	Recruiting	2025-03	China
Nutritional Intervention for Biliary Atresia NCT06764082 · ClinicalTrials.gov ↗ · Nutrition Disorder, Infant, Biliary Atresia	Not applicable	Recruiting	2025-02	China
CD19/BCMA-Targeted UCAR-T for Patients With Neurological Autoimmune Diseases NCT07337785 · ClinicalTrials.gov ↗ · Relapsing or Refractory Multiple Sclerosis (MS), Myasthenia Gravis (MG), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)	Phase EARLY_PHASE1	Recruiting	2025-12	China
Efficacy and Safety of Prophylactic Treatment for Pneumocystis Jirovecii Pneumonia in Patients With Autoimmune Inflammatory Rheumatic Disease NCT06499233 · ClinicalTrials.gov ↗ · Pneumonia, Pneumocystis, Autoimmune Inflammatory Rheumatic Disease, Autoimmune Diseases Drug: Trimethoprim-sulfamethoxazole	Phase 4	Recruiting	2024-07	China
Safety and Efficacy of Telitacicept in the Treatment of Systemic Lupus Erythematosus (SLE) NCT06458972 · ClinicalTrials.gov ↗ · Systemic Lupus Erythematosus	Observational	Recruiting	2024-01	China
JY231 Injection for the Treatment of Relapsed/Refractory Neurologic Immune Disorders NCT06797024 · ClinicalTrials.gov ↗ · Autoimmune Diseases of the Nervous System Drug: JY231	Not applicable	Recruiting	2025-02	China
Stereotactic Thrombolysis With Tenecteplase for Supratentorial Intracerebral Hemorrhage NCT07208097 · ClinicalTrials.gov ↗ · Intracerebral Haemorrhage, Minimally Invasive Treatment	Not applicable	Recruiting	2025-10	China
Adebrelimab Combined With Dalpiciclib and Standard Endocrine Therapy for HR+/HER2 - Advanced Breast Cancer NCT06149130 · ClinicalTrials.gov ↗ · Breast Cancer Drugs: Adebrelimab, Dalpiciclib	Phase 2	Recruiting	2024-01	China
A Non-interventional Registry Study of Fluzoparib in the Treatment of Ovarian Cancer NCT05206890 · ClinicalTrials.gov ↗ · Ovarian Cancer Drug: Fluzoparib	Observational	Recruiting	2022-01	China
The Effects of Sirolimus in Patients With Dilated Cardiomyopathy Infected With Kaposi Sarcoma-associated Virus NCT06236022 · ClinicalTrials.gov ↗ · Dilated Cardiomyopathy, Kaposi's Sarcoma-Associated Herpesvirus Infection	Phase 4	Recruiting	2024-01	China
JY231(JY231) Injection for the Treatment of Relapsed or Refractory B Cell Lymphoma/ Leukemia NCT06689917 · ClinicalTrials.gov ↗ · B-ALL, B-NHL Drug: JY231	Not applicable	Recruiting	2025-01	China
Circulating Tumor Mitochondrial DNA (ct-mtDNA) As a Biomarker for Biliary Tract Cancer Recurrence Surveillance NCT06653127 · ClinicalTrials.gov ↗ · Biliary Tract Cancer	Observational	Recruiting	2024-11	China
Biomarkers in Autoimmune Disease of Nervous System NCT06502015 · ClinicalTrials.gov ↗ · Autoimmune Diseases of the Nervous System, Neuromyelitis Optica Spectrum Disorder, Multiple Sclerosis	Observational	Recruiting	2024-07	China
Deep Learning Model Predicts Pathological Complete Response of Esophageal Squamous Cell Carcinoma Following Neoadjuvant Immunochemotherapy NCT07088354 · ClinicalTrials.gov ↗ · Esophageal Squamous Cell Carcinoma, Neoadjuvant Immunochemotherapy, Pathological Complete Response	Observational	Recruiting	2025-03	China
Ambispective Cohort Study of Precision Medicine for Primary Hepatobiliary Cancer Based on Next-generation Sequencing NCT05520788 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma, Biliary Tract Cancer	Observational	Recruiting	2020-05	China
Safety, Tolerability, and Preliminary Efficacy of KD01 Via Intravesical Instillation in Bladder Cancer (BC) NCT07359235 · ClinicalTrials.gov ↗ · Bladder Cancer (BC) Drug: KD01	Phase 1	Recruiting	2024-11	China
Liposomal Bupivacaine and Bupivacaine for TTMPB in Median Sternotomy NCT06646172 · ClinicalTrials.gov ↗ · Median Sternotomy	Not applicable	Recruiting	2024-10	China
PEG Laxatives for Intestinal Preparation and Gut Microbiota in Cholecystectomy NCT07439640 · ClinicalTrials.gov ↗ · Cholecystectomy	Observational	Recruiting	2025-01	China
Estrogen Receptor (ER) PET/CT Imaging in Breast Cancer NCT05541367 · ClinicalTrials.gov ↗ · Breast Cancer, TNBC - Triple-Negative Breast Cancer, Estrogen-receptor-negative Breast Cancer	Observational	Recruiting	2021-12	China
Opioid-Free Combined Anesthesia With Spontaneous Breathing for VATS NCT06367218 · ClinicalTrials.gov ↗ · Video-assisted Thoracoscopic Lung Surgery；Anesthesia	Not applicable	Recruiting	2024-10	China
HAIC, Lenvatinib, and Cadonilimab as Conversion Therapy for Initially Unresectable Hepatocellular Carcinoma NCT06187961 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma Non-resectable Drugs: Cadonilimab, Lenvatinib	Phase 2	Recruiting	2023-12	China
TSPO-PET/MRI in Surveillance of Neuroinflammation in the Central Nervous System NCT06467773 · ClinicalTrials.gov ↗ · Central Nervous System Diseases	Observational	Recruiting	2024-07	China
Safety and Efficacy of RD133 in Subjects With Relapsed or Refractory MSLN-Positive Solid Tumors NCT05141253 · ClinicalTrials.gov ↗ · Cancer Drug: RD133	Phase EARLY_PHASE1	Recruiting	2022-01	China
Efficacy and Safety of Calculus Bovis Sativus (CBS) for Ischemic Cerebral Vascular Disease (CBSinICVD) NCT06474507 · ClinicalTrials.gov ↗ · Ischemic Cerebrovascular Disease, Acute Ischemic Stroke, Cerebral Small Vessel Diseases Drug: Calculus bovis sativus	Not applicable	Recruiting	2024-08	China
Effects of Fospropofol Disodium TIVA and IVIH on Surgical Field Quality in Adult ESS NCT07788157 · ClinicalTrials.gov ↗ · Fospropofol Disodium Drugs: Fospropofol Disodium, Propofol	Not applicable	Recruiting	2026-07	China
Comparing Laparoscopic and Open Surgery for Pancreatic Carcinoma NCT03785743 · ClinicalTrials.gov ↗ · Pancreatic Carcinoma, Laparoscopic, Pancreaticoduodenectomy	Not applicable	Recruiting	2019-03	China
A Multicenter, Prospective Clinical Trial With a Concurrent Control Evaluating Methotrexate Combined With Rituximab,Sintilimab and Pirtobrutinib vs. Investigator-Selected Standard of Care in Treatment-Naive PCNSL NCT07350850 · ClinicalTrials.gov ↗ · PCNSL, Primary Central Nervous System Lymphoma	Phase 2	Recruiting	2025-12	China
Tegileridine Combined With Intercostal Nerve Block After Thoracoscopic Lung Resection NCT07386626 · ClinicalTrials.gov ↗ · Lobectomy Drugs: Sufentanil, Tegileridine	Not applicable	Recruiting	2026-03	China
Somatostatin Plus Clear Liquid Diet Versus Diverting Stoma in Patients With Rectal Cancer Undergoing Ultra-Low Anterior Resection NCT07605611 · ClinicalTrials.gov ↗ · Rectal Cancer, Anastomotic Leakage Drug: Somatostatin	Not applicable	Recruiting	2025-11	China
The Efficacy and Safety of FRD001 in Ultrasound Contrast Imaging for Malignant Ovarian Masses in Women NCT06556342 · ClinicalTrials.gov ↗ · Ovary Cancer	Not applicable	Recruiting	2024-07	China
A Mixed Cohort, Multicentre Exploratory Study of Non-invasive Quantitative Assessment of Renal Graft Function With Non-contrast Functional Magnetic Resonance Imaging NCT07333495 · ClinicalTrials.gov ↗ · Kidney Transplant, Renal Allograft Recipients, Renal Allograft	Observational	Recruiting	2025-12	China
Human Umbilical Cord Mesenchymal Stem Cell Injection for Diabetic Nephropathy NCT07822152 · ClinicalTrials.gov ↗ · Diabetic Nephropathy Drug: UC-MSCs	Phase 1	Recruiting	2026-03	China
Efficacy and Safety of Calculus Bovis Sativus (CBS) for Idiopathic Inflammatory Demyelinating Disease (CBSinIIDD) NCT06474520 · ClinicalTrials.gov ↗ · Idiopathic Inflammatory Demyelinating Disease, Multiple Sclerosis, Neuromyelitis Optica Spectrum Disorder Drug: Calculus bovis sativus	Not applicable	Recruiting	2024-08	China
CAR-T Therapy Targeting CD19 and BCMA in Highly Sensitized Kidney Transplant Participants NCT07350837 · ClinicalTrials.gov ↗ · Highly Sensitized Patients Awaiting Kidney Transplant Drug: AZD0120	Phase EARLY_PHASE1	Recruiting	2026-01	China
Dose-Effect Response in Acupuncture for Functional Constipation NCT07506122 · ClinicalTrials.gov ↗ · Functional Constipation (FC)	Not applicable	Recruiting	2026-05	China
Study of Predictive Factors Related to Prognosis of Patients With Ischemic Stroke Due to Large-artery Atherosclerosis NCT04847752 · ClinicalTrials.gov ↗ · Ischemic Stroke, Large-Artery Atherosclerosis (Embolus/Thrombosis) Drugs: Aspirin, Clopidogrel	Observational	Recruiting	2021-03	China
Adebrelimab Combined With Gemcitabine, Cisplatin, and Simvastatin for Advanced Biliary Tract Cancer NCT07392541 · ClinicalTrials.gov ↗ · Advanced Biliary Tract Carcinoma	Phase 1/2	Recruiting	2026-01	China
Fecal Microbiota Transplantation as the First-line Treatment in Active Pediatric Crohn's Disease NCT05321758 · ClinicalTrials.gov ↗ · Crohn Disease Drug: Fecal Microbiota Transplantation	Not applicable	Recruiting	2020-03	China
Clinical Efficacy Study of Jinfeng Pill in the Treatment of Perimenopausal Syndrome NCT07606755 · ClinicalTrials.gov ↗ · Perimenopausal Syndrome	Phase 4	Recruiting	2026-05	China
Angong Niuhuang Pills With Different Bovine Bezoar Formulation Sources in the Treatment of AIS NCT06883110 · ClinicalTrials.gov ↗ · Acute Ischemic Stroke	Not applicable	Recruiting	2025-09	China
Safety of Etomidate-propofol Mixture vs. Propofol for Total Intravenous Anesthesia in Elderly Patients Undergoing Abdominal Surgery NCT07019246 · ClinicalTrials.gov ↗ · Etomidate Combined With Propofol, Hypertension Drug: Propofol	Not applicable	Recruiting	2025-02	China
Neoadjuvant Chemoimmunotherapy Versus Concurrent Chemoradiotherapy for LACC NCT06288373 · ClinicalTrials.gov ↗ · Cervical Cancer, Locally Advanced Cervical Cancer, Concurrent Chemoradiotherapy Drugs: Camrelizumab, Cisplatin, Nab-paclitaxel	Phase 2/3	Recruiting	2024-04	China
Effects of Remimazolam and Ciprofol TIVA on PRAE in Pediatric Tonsillectomy and Adenoidectomy NCT07118579 · ClinicalTrials.gov ↗ · Tonsillectomy With or Without Adenoidectomy Drugs: Ciprofol, Propofol, Remimazolam	Phase 4	Recruiting	2025-09	China
Multimodal Deep Learning for Postoperative Liver Cancer Risk Stratification and Intervention NCT07282184 · ClinicalTrials.gov ↗ · Hepotacellular Carcinoma	Phase 1/2	Recruiting	2025-10	China
Effects of Telitacicept vs Cyclophosphamide on Lupus Related Interstitial Lung Disease NCT07077486 · ClinicalTrials.gov ↗ · Lupus or SLE, Interstitial Lung Disease, Systemic Lupus Erythematosus Drugs: Cyclophosphamide, Methylprednisolone	Phase 4	Recruiting	2025-08	China
Clinical Evaluation of New Biomarkers for Ischemic Cerebrovascular Disease NCT06890702 · ClinicalTrials.gov ↗ · Ischemic Stroke, Ischemic Cerebrovascular Disease	Observational	Recruiting	2025-01	China
Prospective Validation of an AI Model for Predicting Liver Metastasis in Colorectal Cancer NCT07392567 · ClinicalTrials.gov ↗ · Colorectal Cancer Liver Metastasis	Observational	Recruiting	2026-01	China
A Study Evaluating the Efficacy of Secukinumab 300mg in Chinese Adults With Active Ankylosing Spondylitis NCT05303285 · ClinicalTrials.gov ↗ · Ankylosing Spondylitis (AS) Drug: Secukinumab	Phase 4	Recruiting	2024-06	China
Neoadjuvant Immunochemotherapy in PD-L1-negative LACC NCT06288360 · ClinicalTrials.gov ↗ · Cervical Cancer, Locally Advanced Cervical Cancer, PD-L1 Negative Drugs: Camrelizumab, Cisplatin, Paclitaxel-albumin	Phase 2	Recruiting	2024-09	China
Headache Registration and Followup Initiated by Tongji Hospital, HUST NCT07269561 · ClinicalTrials.gov ↗ · Headache, Comorbidities	Observational	Recruiting	2024-01	China
Prospective Clinical Database Construction for Liver Cancer Diagnosis and Treatment NCT07587216 · ClinicalTrials.gov ↗ · Liver Cancer (Primary and Metastatic)	Observational	Recruiting	2026-01	China
AI-Based Prediction of Liver Metastasis in Colorectal Cancer (A Retrospective Study) NCT07399236 · ClinicalTrials.gov ↗ · Colorectal Cancer Liver Metastases (CRLM)	Observational	Recruiting	2015-01	China
Equecabtagene Autoleucel Injection (Eque-cel) for Relapsed/Refractory Systemic Lupus Erythematosus (SLE) NCT06902844 · ClinicalTrials.gov ↗ · Systemic Lupus Erythematosus (SLE), Lupus Nephritis (LN) Drug: Equecabtagene Autoleucel	Not applicable	Recruiting	2025-04	China
Safety and Efficacy of PRG-1801 for Refractory Lupus Nephritis and IgG4-Related Disease NCT06497387 · ClinicalTrials.gov ↗ · Lupus Nephritis, IgG4-related Disease	Phase EARLY_PHASE1	Recruiting	2024-07	China
Safety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous System NCT04561557 · ClinicalTrials.gov ↗ · Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Neuromyelitis Optica Spectrum Disorder	Phase EARLY_PHASE1	Recruiting	2020-09	China
Tislelizumab Combined With Huaier Granule as First-line Treatment for Unresectable Hepatocellular Carcinoma NCT07413354 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma (HCC) Drugs: Huaier, Tislelizumab	Phase 2	Recruiting	2026-04	China
Combined HAIC, Lenvatinib and Pucotenlimab as Conversion Therapy for Unresectable Intrahepatic Cholangiocarcinoma NCT06192797 · ClinicalTrials.gov ↗ · Cholangiocarcinoma Non-resectable Drugs: Lenvatinib, Pucotenlimab	Phase 2	Recruiting	2024-06	China
Influenza Vaccination After Acute Coronary Syndrome NCT07259252 · ClinicalTrials.gov ↗ · Acute Coronary Syndromes (ACS)	Not applicable	Recruiting	2025-12	China
Observing the Efficacy and Safety of Different Drugs Used in Real-world Familial Mediterranean Fever (FMF) Cases NCT07077473 · ClinicalTrials.gov ↗ · Familial Mediterranean Fever (FMF )	Observational	Recruiting	2018-01	China
Impact of Emotional Disorders on Response to Immune Checkpoint Inhibitor Therapy in Liver Cancer NCT07325565 · ClinicalTrials.gov ↗ · Liver Cancer, Emotional Disorder	Observational	Recruiting	2025-12	China
The Application of an AI-driven Multimodal Predictive Model for Cognitive Impairment in Patients With Type 2 Diabetes Mellitus NCT07128186 · ClinicalTrials.gov ↗ · Cognitive Dysfunction	Observational	Recruiting	2025-04	China
A Clinical Study Exploring CT1190B in the Treatment of Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma ( CT1190B-CG11001 ) NCT07053670 · ClinicalTrials.gov ↗ · B-Cell Non-Hodgkin Lymphoma	Phase 1	Recruiting	2025-07	China
FOLFOX-HAIC as Conversion Treatment for Initially Unresectable Colorectal Liver Metastasis NCT06988852 · ClinicalTrials.gov ↗ · Colorectal Liver Metastasis (CRLM)	Phase 2	Recruiting	2023-05	China
Effects of Ciprofol on Myocardial Injury After Non-cardiac Surgery in Video-Assisted Thoracoscopic Surgery NCT07028593 · ClinicalTrials.gov ↗ · Myocardial Injury, Thoracic Diseases, Thoracoscopic Surgery Drugs: Ciprofol, Propofol	Phase 4	Recruiting	2025-07	China
Monoclonal Antibody-Based Therapies for AQP4-Positive NMOSD NCT06885957 · ClinicalTrials.gov ↗ · NMO Spectrum Disorder	Observational	Recruiting	2025-07	China
AI-Based Prediction of HCC Recurrence Patterns After Resection (APAR) NCT07062380 · ClinicalTrials.gov ↗ · Hepatecellular Carcinoma, Hepatectomy	Observational	Recruiting	2025-06	China
Perioperative Quantitative Sensory Testing and Incision Pain Mapping in Thoracic Surgery NCT07653932 · ClinicalTrials.gov ↗ · Postoperative Pain, Chronic Postsurgical Pain, Thoracic Surgery	Observational	Not yet open	2026-06	China
Denosumab Strategy for Liver Cancer With Bone Metastases NCT07537972 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma (HCC), Bone Metastases Drugs: Denosumab, Sintilimab	Phase 2	Not yet open	2026-05	China
A Study to Evaluate Sintilimab Plus Lenvatinib as Adjuvant Therapy in Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis (PVTT) After Surgical Resection NCT06089382 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma Drugs: Lenvatinib, Sintilimab	Phase 3	Not yet open	2023-11	China
Predictors of Epidural Depth in Percutaneous Nephrolithotomy and Model Development NCT07697053 · ClinicalTrials.gov ↗ · Epidural Anesthesia, Percutaneous Nephrolithotomy (PCNL)	Observational	Not yet open	2026-06	China
Predictive Value of Minimal Residual Disease for Postoperative Recurrence and Adjuvant PD-1 Inhibitor in HCC NCT07350824 · ClinicalTrials.gov ↗ · HCC, Minimal Residual Disease, Recurrence	Not applicable	Not yet open	2025-12	China
SHR - A1811 Versus Chemotherapy for Platinum-resistant Recurrent Epithelial Ovarian Cancer NCT06990503 · ClinicalTrials.gov ↗ · Ovarian Cancer Drug: Trastuzumab Rezetecan	Phase 3	Not yet open	2025-06	China
Tauroursodeoxycholic Acid Combined With PD-1/PD-L1 Immunotherapy in Advanced Hepatocellular Carcinoma: A Prospective Study NCT07064668 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma Drug: TUDCA (Tauroursodeoxycholic Acid) Supplementation	Phase 2	Not yet open	2025-07	China
A Clinical Study of Chinese Herbal Formula TJAOA103 in Treating Genitourinary Syndrome of Menopause NCT07160127 · ClinicalTrials.gov ↗ · Genitourinary Syndrome of Menopause (GSM)	Phase EARLY_PHASE1	Not yet open	2025-09	China
Tongji NADs Cohort NCT07333196 · ClinicalTrials.gov ↗ · Multiple Sclerosis, NMO Spectrum Disorder, Autoimmune Encephalitis	Observational	Not yet open	2026-03	China

Showing the 100 most recently updated of 142 trials (recruiting first). The rest are in the country registers linked in each row.

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

Drugs in Tongji Hospital trials

57 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

+ 17 more in the trial list above.

Conditions in Tongji Hospital trials

213 conditions

Ovarian Cancer7 Hepatocellular Carcinoma (HCC)6 Cervical Cancer6 Neoadjuvant Chemoimmunotherapy4 Hepatocellular Carcinoma4 Multiple Sclerosis4 HCC3 Breast Cancer3Autoimmune Diseases of the Nervous System3Neuromyelitis Optica Spectrum Disorder3Thoracic Surgery2Autoimmune Encephalitis (AE)2Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)2Autoimmune Encephalitis2Esophageal Squamous Cell Carcinoma2 Lupus Nephritis2 IgG4-related Disease2NMO Spectrum Disorder2Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease2Autoimmune Diseases2 Systemic Lupus Erythematosus2 Crohn Disease2 Biliary Tract Cancer2 Overweight2

By trial register

Register	Trials	Recruiting
Clinical trials in China	142	91

A trial with sites in more than one country appears in each of those registers; recruiting counts cover the trials listed on this page.

Other sponsors in Ovarian Cancer

Sponsor	Trials
Xencor	3
Anhui Provincial Cancer Hospital	3
Hangzhou SynRx Therapeutics Biomedical Technology	3
Genmab	2
Tubulis	2
USWM CT	2
BeiGene	2
Imunon	2
CanariaBio	2
Chongqing University Cancer Hospital	2

Sponsors with the most current trials registered for this condition.

Questions about Tongji Hospital trials

How many clinical trials does Tongji Hospital sponsor?

Tongji Hospital is the lead sponsor of 142 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Tongji Hospital trials recruiting?

Yes. 91 of its 142 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Tongji Hospital testing?

Its current trials name 57 drugs and biologicals as interventions. The most frequent are Cisplatin (5), Lenvatinib (5), Sintilimab (5), Calculus bovis sativus (4) and Propofol (4). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, lead sponsor, phase, overall status, start date, conditions and intervention names
EU Clinical Trials Information System (CTIS) ↗ EU trial numbers, titles, sponsor, phase, status, therapeutic area and member-state countries

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.

Tongji Hospital clinical trials